% 0期刊文章%公元诺登% g s年轻% k . Setayesh % A . Muzikansky % A R . Klufas % g·l·罗斯% s Ciampa % l . g . Ebbeling %征收B % J . Drappatz % s Kesari % P y温家宝为复发性恶性神经胶质瘤% B % T贝伐单抗疗效、毒性、复发和模式2008% % D R 10.1212/01. wnl.0000304121.57857.38 % J神经病学% P 779 - 787 V % 70% 10% N X背景:贝伐单抗,人源化单克隆抗体对血管内皮生长因子,在复发性恶性神经胶质瘤可能活动。首页在复发有些病人出现开发nonenhancing浸润而不是增强肿瘤疾病。方法:我们回顾了连续55复发性恶性神经胶质瘤患者接受贝伐单抗和化疗来确定疗效,毒性和复发的模式。使用盲法,标准化的成像检查和定量体积分析,与贝伐单抗治疗的患者的复发模式相比,复发模式仅19个病人接受化疗。结果:总共有2.3%的患者完全缓解,31.8%部分反应,29.5%的最小响应,29.5%有稳定的疾病。中位数时间射线级数为19.3周。六个月的无进展生存(PFS)是42%,胶质母细胞瘤患者为32%,未分化神经胶质瘤患者。在23个患者初始治疗进展,贝伐单抗是继续和并发化疗剂改变了。在任何情况下的变化产生射线反应,但两个病人长期PFS 20 - 31周。递归模式分析确定了显著增加渗透性的肿瘤的体积相对于加强贝伐单抗肿瘤反应者。 Conclusions: Combination therapy with bevacizumab and chemotherapy is well-tolerated and active against recurrent malignant gliomas. At recurrence, continuing bevacizumab and changing the chemotherapy agent provided long-term disease control only in a small subset of patients. Bevacizumab may alter the recurrence pattern of malignant gliomas by suppressing enhancing tumor recurrence more effectively than it suppresses nonenhancing, infiltrative tumor growth. AA=anaplastic astrocytoma; AG=anaplastic glioma; CR=complete response; GBM=glioblastoma; EIAED=enzyme-inducing antiepileptic drug; FLAIR=fluid-attenuated inversion recovery; KPS=Karnofsky Performance Status; MR=minimal response; PFS=progression-free survival; PR=partial response; rFPR=relative FLAIR progression ratio; rNTR=relative nonenhancing tumor ratio; T1W=T1-weighted; VEGF=vascular endothelial growth factor. %U //www.ez-admanager.com/content/neurology/70/10/779.full.pdf